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Abstract
A large number of recent genome-wide association studies (GWASs) for complex phenotypes
confirm the early conjecture for polygenicity, suggesting the presence of large number of variants
with only tiny or moderate effects. However, due to the limited sample size of a single GWAS,
many associated genetic variants are too weak to achieve the genome-wide significance. These
undiscovered variants further limit the prediction capability of GWAS. Restricted access to the
individual-level data and the increasing availability of the published GWAS results motivate the
development of methods integrating both the individual-level and summary-level data. How
to build the connection between the individual-level and summary-level data determines the
efficiency of using the existing abundant summary-level resources with limited individual-level
data, and this issue inspires more efforts in the existing area.
In this study, we propose a novel statistical approach, LEP, which provides a novel way
of modeling the connection between the individual-level data and summary-level data. LEP
integrates both types of data by LEveraing Pleiotropy to increase the statistical power of
risk variants identification and the accuracy of risk prediction. The algorithm for parameter
estimation is developed to handle genome-wide-scale data. Through comprehensive simulation
studies, we demonstrated the advantages of LEP over the existing methods. We further applied
LEP to perform integrative analysis of Crohn’s disease from WTCCC and summary statistics
from GWAS of some other diseases, such as Type 1 diabetes, Ulcerative colitis and Primary
biliary cirrhosis. LEP was able to significantly increase the statistical power of identifying risk
variants and improve the risk prediction accuracy from 63.39% (± 0.58%) to 68.33% (± 0.32%)
using about 195,000 variants.
The LEP software is available at https://github.com/daviddaigithub/LEP.
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1 Introduction
The explosive growth of genome-wide association studies (GWASs) is leading to a new era for
understanding the genetic underpinnings of complex phenotypes. As of March 2018, more than 3,300
GWASs have been conducted for hundreds of complex traits, about 59,000 statistically significant
(at the genome-wide p-value threshold of 5 × 10−8) associations between genetic variants and the
complex traits have been reported [Welter et al., 2014]. However, most of these variants contribute
relatively small increments of risk and only explain a small portion of variation in complex diseases.
Recently, many GWASs have suggested that complex diseases are affected by the collective effects
of many genetic variants, each of which may have only a small effect, known as ‘polygenicity’
[Visscher et al., 2017, Yang et al., 2016]. Due to the limited sample size of a single GWAS, many of
the individual effects of genetic variants could not achieve the genome-wide significance and thus
remain undiscovered.
Although the available experimental sample sizes have dramatically increased in many recent
studies, a comprehensive integration over the existing data resources may further advance our
understandings of complex traits [Flannick and Florez, 2016, Khera and Kathiresan, 2017]. To
this end, many methods have been proposed to improve the analysis by combining datasets from
resources of multiple biological platforms. These methods could be divided into three categories
according to their inputs of different data types. The methods in the first group (e.g., [Li et al.,
2014]) work with related individual-level datasets to achieve better performance by jointly analyzing
individual-level data from different sources. As the availability of summary statistics from GWASs
increases, the methods in the second group (e.g., [Chung et al., 2014, Liu et al., 2016, 2017, Mak
et al., 2017, Turley et al., 2018, Zhu et al., 2015]) working with summary statistics are more
convenient to be applied because the summary-level data sets are easily accessible. (see the detailed
review of these methods in [Pasaniuc and Price, 2017]). Compared to the methods in the first group,
the methods in the second group have the advantage of computation, but they might sacrifice
statistical efficiency. To make the most efficient use of the available resources of GWAS data,
the methods in the third group work with both individual-level data and summary-level data
simultaneously, e.g., [Dai et al., 2017, Purcell et al., 2009, Shi et al., 2016].
The methods in the third group (e.g., IGESS [Dai et al., 2017]) often make a homogeneous
assumption for risk variants, i.e., all risk variants are assumed to be shared in the individual-level
data and the summary-level data. This assumption makes sense when the individual-level data
and the summary-level data correspond to the same disease and the samples are from the same
population. However, such a requirement can be too restricted to allow this group of method to make
most efficient use of existing data resources. In fact, GWASs have identified genetic variants that can
affect multiple seemly different complex traits. This phenomenon has been known as ‘Pleiotropy’
[Stearns, 2010]. Accumulating evidence suggests pleiotropy widely exists among complex diseases
[Yang et al., 2015, Sivakumaran et al., 2011], such as autoimmune diseases [Cotsapas et al., 2011]
and psychiatric disorders [Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013].
Examples include: SNP rs1800693 in the major TNF-receptor gene (TNFR1 ) implicated in multiple
sclerosis (MS) has also been associated with ankylosing spondylitis (AS) [Visscher et al., 2017];
the protein tyrosine phosphatase non-receptor type 22 (PTPN22 ) is associated with rheumatoid
arthritis (RA) and systemic lupus erythematosus (SLE) [Begovich et al., 2004]. Therefore, it is
necessary to get rid of the homogeneous assumption and effectively integrate individual-level data
and summary-level data by leveraging abundant pleiotropic information among complex traits.
In this study, we propose a statistical approach, LEP, to integrate both the individual-level and
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summary-level data by LEveraging Pleiotropy when the corresponding traits are of a pleiotropic
relationship. An efficient variational-inference-based algorithm has been developed such that it can
fit the model in an efficient manner. Not only does LEP make efficient use of GWAS data but also
provides a new way of characterizing the pleiotropy. Through comprehensive simulation studies,
we demonstrated the effectiveness of LEP by leveraging pleiotropy in the presence of heterogeneity
among the individual-level and summary-level data, which takes the advantages over the existing
methods. We then applied LEP to perform integrative analysis on individual-level data of Crohn’s
disease from WTCCC and summary statistics of some other diseases. LEP was able to significantly
increase the statistical power of identifying risk variants, and correspondingly improve the risk
prediction.
2 LEP
2.1 Model
Given a trait named T, suppose we have an individual-level genotype data set X ∈ RN×M from N
individuals and their corresponding phenotypes y ∈ RN , whereM is the number of SNPs. Without
loss of generality, we assume both X and y have been centered. In addition, we collect summary
statistics, i.e., p-values from K independent GWASs in matrix P = [pjk] ∈ RM×K , where pjk
corresponds to the p-value of the j-th SNP in the k-th GWAS. Suppose these K GWASs are for K
different traits, each of which shares certain associated variants with trait T. First, we consider the
following linear model for the genotype data,
y = Xβ + e, (1)
where β = [β1, . . . , βM ]T is a vector of effect sizes, and e is the independent random error with the
distribution N(e|0, σ2eI). The identification of risk variants is equivalent to the variable selection
in Eq. (1). A binary variable γj is introduced to indicate whether βj is zero or not. Assuming the
spike-and-slab prior [Mitchell and Beauchamp, 1988] for βj ,
βj |γj , σ2β ∼
{
N(βj |0, σ2β) if γj = 1,
δ0(βj) if γj = 0,
(2)
where βj from the slab group follows a Gaussian distribution N(βj |0, σ2β) and βj from the spike
group corresponds to the Dirac function centered at zero, and γj is assumed to follow the Bernoulli
distribution Bern(γj |pi),
γj |pi ∼ piγj (1− pi)1−γj . (3)
Second, we assume that the p-values from the k-th GWAS follow a mixture distribution, a binary
variable Γjk is introduced to indicate whether the j-th SNP is associated with the k-th trait,
pjk|Γjk, αk ∼
{
U(0, 1) if Γjk = 0,
Beta(pjk|αk, 1) if Γjk = 1,
(4)
where p-values from the null group follow the uniform distribution U(0, 1) and p-values of the k-th
study from the non-null group follow the Beta distribution with parameter (αk, 1).
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To model the pleiotropic relationship between trait T and k-th trait of summary statistics, we
define,
uk := Pr(Γjk = 1|γj = 1),
vk := Pr(Γjk = 0|γj = 0).
(5)
Here uk is the conditional probability that a variant is associated with the k-th trait given that
this variant is associated with trait T, and vk is defined for the opposite case. The introduction of
these two parameters enables the proposed model to adapt to the heterogeneous cases which cover
the homogeneous case (uk = 1, vk = 1) as a special case. The pair of parameters characterizes the
degree of pleiotropic effects of trait T and the k-th trait.
Furthermore, we assume Γ1j , . . . ,ΓjK are conditional independent given γj , denote Γ = [Γjk] ∈
RM×K . Then we have
Pr(Γ|γ) =
M∏
j=1
K∏
k=1
Pr(Γjk|γj). (6)
Let θ = {pi, σ2β , σ2e , {αk, uk, vk}Kk=1} be the collection of model parameters. The probabilistic model
can be written as
Pr(y,P,β,Γ,γ|X;θ)
=Pr(y|X,β;θ)Pr(β|γ;θ)Pr(γ|θ)Pr(P|Γ;θ)Pr(Γ|γ;θ). (7)
Its graphical representation could be referred in Fig. 1.
We aim to obtain θˆ (the estimate of θ) by maximizing the marginal likelihood
Pr(y,P|X;θ) =
∑
γ,Γ
ˆ
β
Pr(y,P,β,γ,Γ|X;θ)dβ, (8)
and then have the posterior of latent variable {β,γ,Γ} as Pr(β,γ,Γ|y,X,P; θˆ). Although the above
LEP model was designed for the traits with the Gaussian noise, we may use the logit or probit link
function for handling case-control studies. Empirical results (e.g., [Dai et al., 2017]) suggest the
performance of generalized linear models does not show significant improvements if the sample size
is moderate (e.g., a few thousands) while the computation burden might be more expensive. In fact,
the effectiveness of linear models applied for the analysis of case-control GWAS datasets has been
justified in [Kang et al., 2010]. Therefore, we developed LEP based on the Gaussian assumption,
and demonstrate its effectiveness on the case-control studies by both simulation study and real data
analysis.
2.2 Algorithm
The intractability of the exact evaluation of Eq. (8) sets up a challenge for solving the model.
To address this challenge, we derive an efficient algorithm based on variational inference [Bishop,
2006]. To get rid of the Dirac function, the reparametrization is conducted as follows. Assume
β˜j follows a Gaussian distribution N(β˜j |0, σ2β) and γj follows a Bernoulli distribution Bern(γj |pi),
respectively. Clearly, their product β˜jγj follows the same distribution as βj in Eq. (2). With this
reparametrization, the joint model Eq. (7) becomes
Pr(y,P, β˜,γ,Γ|X;θ)
=Pr(y|X, β˜,γ;θ)Pr(β˜;θ)Pr(γ|θ)Pr(P|Γ;θ)Pr(Γ|γ;θ), (9)
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where
Pr(y|X, β˜,γ;θ) = N(y|
∑
j
xj β˜jγj , σ2eI),
Pr(β˜|θ) =
M∏
j
N(β˜j |0, σ2β),
Pr(γ|θ) =
M∏
j
piγj (1− pi)1−γj ,
Pr(P|Γ;θ) =
M∏
j
K∏
k
(
αkp
αk−1
jk
)Γjk
,
Pr(Γ|γ;θ) =
M∏
j
K∏
k
Pr(Γjk|γj).
Clearly, the Dirac function is not involved and the prior of β˜j does not depend on γj after
reparametrization. Next, we aim to find a variational approximation q(β˜,γ,Γ) to the true posterior
Pr(β˜,γ,Γ|y,X,P;θ). Then we will have a lower bound of the logarithm of the marginal likelihood
log Pr(y,P|X;θ)
= log
∑
γ,Γ
ˆ
β˜
Pr(y,P, β˜,γ,Γ|θ)dβ˜
≥
∑
γ,Γ
ˆ
β˜
q(β˜,γ,Γ) log Pr(y,P, β˜,γ,Γ|X;θ)
q(β˜,γ,Γ)
dβ˜
=Eq[log Pr(y,P, β˜,γ,Γ|X;θ)− log q(β˜,γ,Γ)]
:=L(q),
(10)
where the inequality follows Jensen’s inequality, and the equality holds if and only if q(β˜,γ,Γ) is
the true posterior Pr(β˜,γ,Γ|y,P,X;θ). Now, we can iteratively maximize L(q) instead of directly
working with the marginal log-likelihood. To make it feasible to evaluate this lower bound, we
assume that q(β˜,γ,Γ) can be factorized as
q(β˜,γ,Γ) =
M∏
j=1
qj(β˜j , γj ,Γj),
where Γj = [Γjk] ∈ R1×K . This is the only assumption we made in the variational inference.
According to the property of factorized distributions in variational inference [Bishop, 2006], we can
obtain the best approximation as
log qj(β˜j , γj ,Γj) = Ei 6=j [log Pr(y,P, β˜,γ,Γ|X;θ)] + Const,
where the expectation is taken with respect to all of the other factors {qi(β˜i, γi,Γi)} for i 6= j. As
q(β˜j , γj ,Γj) = q(β˜j |γj)q(Γj |γj)q(γj), after some derivations (refer to Section 1.1 of Supplementary
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document), we have
q(β˜j , γj ,Γj) =
(
pijN(β˜j |µj , s2j )
K∏
k=1
q(Γjk|γj = 1)
)γj
(
(1− pij)N(β˜j |0, σ2β)
K∏
k=1
q(Γjk|γj = 0)
)1−γj
,
(11)
where
s2j =
σ2e
xTj xj +
σ2e
σ2
β
,
µj =
xTj y−
∑
i6=j Eq[γiβ˜i]xTj xi
xTj xj +
σ2e
σ2
β
, (12)
and
pij =
1
1 + exp(−wj) ,
wj = log
pi
1− pi +
1
2 log
s2j
σ2β
+
µ2j
2s2j
+
K∑
k=1
log
αkp
αk−1
jk uk + 1− uk
αkp
αk−1
jk (1− vk) + vk
. (13)
Since q(β˜,γ,Γ) is an approximation to the true posterior, the above result (11) can be interpreted
as follows. Here pij can be viewed as an approximation of Pr(γj = 1|y,X,P;θ). As we can
observe from Eq. (13), pij is influenced by three sources of information: the first term is the prior
information of expected proportion of variants contributed to the variance of phenotype T, the
second term 12 log
s2j
σ2
β
+ µ
2
j
2s2
j
corresponds to the information provided by the genotype data and the
third term
K∑
k=1
log
αkp
αk−1
jk uk + 1− uk
αkp
αk−1
jk (1− vk) + vk
corresponds to the information provided by the summary-
level data. It is clear that the same stringent p-value in the GWAS with stronger pleiotropic
relationship indicates a greater probabilistic association with the individual-level data. On the
other hand, when SNP j is irrelevant to the phenotype (γj = 0), the approximated posterior of β˜j
remains the same as its prior, i.e., β˜j ∼ N(β˜j |0, σ2β); When SNP j is relevant (γj = 1), its posterior
changes accordingly as β˜j ∼ N(β˜j |µj , s2j ).
With qj(β˜j , γj ,Γj) given in (11), the lower bound
L(q) = Eq[log Pr(y, β˜,γ,Γ,P|X,θ)]− Eq[log q(β˜,γ,Γ)]
can be evaluated in a closed form. By taking derivative of L(q) with respect to each parameter in θ
and setting them to zero, we can obtain the updating equations for parameter estimation (details
in Section 1.2 of the Supplementary document).
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Figure 1: Graphical Model of LEP, the circles denote the observed or unobserved randoms variables,
the shaded circles denote the observed ones. Other nodes are those fixed variables or parameters.
In summary, our algorithm can be viewed as a variational expectation-maximization (EM)
algorithm. In the expectation step, we evaluate the expectation with respect to the distribution q
to obtain the lower bound L(q) given in Eq. (10). In the maximization step, we maximize the current
L(q) with respect to model parameters in θ. Hence, the convergence of the proposed algorithm is
guaranteed as the lower bound increases in each EM iteration.
2.3 Identification of risk variants and risk prediction
Given a genotype vector x˜ = [x˜1, . . . , x˜M ]T of an individual, the well-trained LEP model conducts
the risk prediction by computing
yˆ = c0 +
∑
j
x˜jE(γj β˜j) = c0 +
∑
j
x˜jpijµj . (14)
Here pij in Eq. (14) is also an approximation to the true posterior Pr(γj = 1|y,P,X;θ) for SNP
j, as Pr(γj = 0|y,P,X;θ) is the definition of local false discovery rate (FDR) of SNP j (Efron
[2010]), we denote fdrj = 1− pij as the approximation of local FDR, SNP j would be labeled as a
risk variant if fdrj approaches 0, e.g. fdrj ≤ 0.05.
3 RESULTS
3.1 Simulation
In this section, we conducted simulation studies to evaluate the performance of LEP in terms of
both the risk variants identification and the risk prediction. The performance of the identification
of risk variants was evaluated in comparison with BVSR [Carbonetto and Stephens, 2012], Lasso
[Tibshirani, 1996] (only with individual-level data), IGESS [Dai et al., 2017] and GPA [Chung et al.,
2014]. Note that IGESS was based on a homogeneous assumption, i.e. Γ1j = Γ2j = . . .= Γjk =
γj , while GPA only worked for summary-statistics data. Then, the prediction accuracy of LEP
was evaluated in comparison with BVSR, Lasso and IGESS. In the spirit of reproducibility, all the
simulation codes were made publicly available at https://github.com/daviddaigithub/LEP.
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Figure 2: Comparison of BVSR, GPA, IGESS and Lasso with different {u, v}. Left panel: perfor-
mance of risk variant identification measured by AUC; Right panel: performance of risk prediction.
The number of summary-level datasets K = 1. All the results are summarized based on 50 replica-
tions.
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Figure 3: Comparison of BVSR, GPA, IGESS and Lasso with different K. Left panel: performance
of risk variant identification measured by AUC; Right panel: performance of risk prediction. The
indicator uk = 0.5 and sparsity-level s = 0.05 . All the results are summarized based on 50
replications.
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3.1.1 Simulation settings
Both the individual-level and summary-level data were simulated in our experiments. In order to
mimic the linkage disequilibrium (LD) of the individual-level data, the genotype matrix X was
first generated by a zero-mean Gaussian distribution with a autoregressive structure for the co-
variance matrix, where the autoregressive correlation ρ|j−j′| indicated the correlation between the
two corresponding variants. Clearly, ρ = 0 corresponded to the situation that all the variants were
independent. We considered ρ = {0, 0.2, 0.4, 0.6, 0.8} in our simulations. Then each column of X
was numerically coded as {0, 1, 2} with probability (1−f)2, 2f(1−f) and f2, respectively, according
to Hardy-Weinberg principle, where f was the minor allele frequency (MAF). We fixed the number
of samples as N = 2, 000, the number of variants as M = 10, 000, and the sparsity-level s = 0.05.
On average, M · s nonzero entries in the vector of effect sizes β were generated using N(0, 1). The
phenotype vector was generated as y = Xβ + e, where the variance of e was adjusted such that
heritability, i.e., var(Xβ)/var(y) was fixed at 50%.
The simulated p-values were obtained from the individual-level data instead of the generative
model (Eq. (4)). Because the released summary-level data sets often have much larger sample sizes,
we used n0 = 8, 000 samples to generate summary statistics, i.e., p-values in our simulation. We
generated individual-level genotype data X(k), as what we described above. To simulate the vector
of effect size β(k), we assume the k-th trait has the same of proportion of nonzero entries as the
trait T, that is sk = s. We generated the nonzero entries according to (uk, vk) in Eq. (5) where
(uk, vk) satisfied uks+ (1− vk)(1− s) = s, i.e., probability relationship,
Pr(Γjk = 1) =Pr(Γjk = 1|γj = 1)Pr(γj = 1)
+ Pr(Γjk = 1|γj = 0)Pr(γj = 0).
Again, the nonzero entries were drawn from N(0, 1), and the k-th phenotype vector was generated
as yk = Xkβk + ek, where the variance of ek was specified such that the heritability of the
k-th phenotype was 50%. Then we obtained p-values of each variant by applying simple linear
regression. To evaluate the performance of different methods, we pretended that we can not access
the individual level data set but can only use the summary-level data, i.e. p-value matrix P ∈
RM×K .
For LEP and IGESS, both the individual-level data {X,y} and the p-value matrix P were used.
For BVSR and Lasso, only the individual-level data set {X,y} was used, and their performance
could serve as a baseline. For GPA, anM×2 matrix P containing the p-values from {X,y} and the
p-values from the first study {X(1),y(1)} was used as its input. We present the results of analyzing
quantitative phenotype simulated as above in the main text and leave the results of case-control
study in the Supplementary document.
3.1.2 Results
We conducted the comparisons in four scenarios and evaluated the performance of both risk variants
identification and risk prediction. The performance of risk variants identification was measured by
the area under the receiver operating characteristic (ROC) curve (AUC), and the performance of
risk prediction was measured by the correlation between the observed phenotype values and the
predicted values.
First, we fixed K = 1, and varied u at {0.9, 0.7, 0.3, 0.05} to mimic different pleiotropic settings
to see the benefits of LEP. According to the condition of independence (u+v=1, see the detailed
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derivation in the Supplementary document), the parameter setting u = 0.05 (v = 0.95) corresponds
to the situation that the trait of the summary-level data are irrelevant to the trait of the individual-
level data. The pleiotropic effect between two traits increases as u increases from 0.3 to 0.9.
Fig. 2 shows the performance of risk variants identification and prediction under different pleiotropy
settings. Here BVSR and Lasso using only individual-level data were used to serve as a baseline.
In terms of risk variants identification, when the pleiotropic effect between two traits is high (u
= {0.7, 0.9}), LEP, GPA and IGESS outperform BVSR working only with the individual-level
dataset; when the pleiotropic effect is weak (u = 0.3), LEP and GPA still perform better than
BVSR. Moreover, when there is no relevant summary information (u = 0.05), the performance of
LEP is comparable to BVSR, which shows the robustness of LEP in the absence of useful summary
information. It has similar results in terms of risk prediction. LEP and IGESS outperform BVSR
and Lasso when the pleiotropic effect is high (u = {0.7, 0.9}). When the pleiotropic effect is weak
(u = 0.3), LEP outperforms BVSR; When the summary-level data is irrelevant, LEP is slightly
worse than Lasso, but is comparable with BVSR.
Second, we fixed uk := Pr(Γjk = 1|γj = 1) = 0.5, and varied the number of study with summary
statistics at K = {1, 3, 5} to see the improvements when more information was incorporated.
Fig. 3 shows the improvement of LEP in comparisons with GPA, IGESS, BVSR and Lasso as K
increases. When K = 1, GPA, IGESS and LEP all outperform BVSR as they use more information.
LEP outperforms GPA as there is more useful information from the individual-level data. The
performance of LEP increases as the number of K increases. One can observe that IGESS has
comparable performance to LEP but it can not control the FDR as shown in the Supplementary
document. Instead, LEP is a method that could borrow strength from the study of a pleiotropic
relationship and also control the FDR at the pre-specified level. All the results with respect to
FDR, the power of risk variants identification are presented in the Supplementary document.
Last, we considered an extreme situation, the association status Γ·k (the k-th column of Γ) was
exactly the same as γ, which was the assumption of IGESS, and the results are presented in the
Supplementary document.
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Figure 4: Prediction accuracy measured by AUC with different summary-level data. The plus sign
‘+’ means jointly analyzing CD and summary-level data for certain trait (s); T_U_P means jointly
analyzing with T1D, UC and PBC; T_U_P_A_N means jointly analyzing with T1D, UC, PBC,
AZ and NC. The results are based on 30 replications.
In summary, all the simulation results suggest that LEP is a reliable method when incorporating
information from various kinds of summary statistics. It could make the most efficient use of the
information as well as control the FDR well. Moreover, it will not degenerate the performance of
analyzing individual-level data even when the summary statistics are from the irrelevant studies.
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Figure 5: Manhattan plots of the analysis results of Crohn’s Disease using LEP. T_U_P means
jointly analyzing with T1D, UC and PBC; T_U_P_A_N means jointly analyzing with T1D, UC,
PBC, AZ and NC. The red lines and blue lines correspond to fdr = 0.05 and fdr = 0.1 respectively.
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Table 1: Pleiotropy for the five data set with u,v
GWAS u v
1 Ulcerative Colitis 1.0000 0.9260
2 Primary biliary cirrhosis 0.9998 0.9744
3 Type 1 diabetes 0.9986 0.9176
4 Alzheimer 2.72e-05 0.9325
5 Neuroticism 2.32e-03 0.7759
3.2 Real Data Analysis
We applied LEP to analyze GWAS data of Crohn’s disease (CD) with summary statistics from some
other autoimmune diseases. The individual-level data is from the Welcome Trust Case Control
Consortium (WTCCC) [Burton et al., 2007]. There are 5,009 samples, of which 2,005 are cases
and 3,004 are controls. The summary-level datasets are for Ulcerative colitis (UC), Primary biliary
cirrhosis (PBC), Type 1 diabetes (T1D), three autoimmune-type diseases, are expected to be helpful
in jointly analyzing with CD. In order to demonstrate the robustness of LEP on real data analysis,
we selected two GWASs for Alzheimer (AZ), Neuroticism (NC), which were not relevant to CD by
our common sense.
3.2.1 Quality Control on the individual-level data
The strict quality control (QC) on the individual-level data from WTCCC was performed by using
PLINK [Purcell et al., 2007] and GCTA [Yang et al., 2011]. First, we removed the individuals
that has more than 2% missing genotypes; Before combining the CD dataset and the two control
datasets, the SNPs with MAFs < 0.05 and those with missing rate > 1% were removed. Then we
removed the SNPs with p-value < 0.0001 in Hardy-Weinberg equilibrium test and kept one of the
relatives with estimated relatedness > 0.025 identified by GCTA [Yang et al., 2011] on the combined
dataset. After QC, there were 1,656 cases and 2,880 controls remaining with 308,950 SNPs.
3.2.2 Summary-statistic data preprocessing
The details of the summary-level data were listed in Table S1 in Supplementary document. Taking
overlapped SNPs among individual-level data and all the five phenotypes led to the individual-level
data X ∈ RN×M ,y ∈ RN×1 and a p-value matrix P ∈ RM×K , where N = 4, 536, M = 194, 782
and K = 5.
3.2.3 Analysis of pleiotropy with each single phenotype
We applied LEP to analyze the individual-level data for Crohn’s Disease with each of the five
phenotypes. The results are listed in Table 1. The greater value of u indicates a stronger pleiotropic
relationship between the corresponding disease and the Crohn’s Disease. The values {u, v} for
Alzheimer and Neuroticism indicate that they almost share no associated variants with Crohn’s
disease.
3.2.4 Analysis result of Crohn’s Disease
After analyzing the pleiotropy of each dataset with summary statistics, we then applied LEP to
analyze CD with the selected summary statistics of PBC, T1D, UC, AZ and NC. The results for
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prediction accuracy and Manhattan plots of genome-wide hits are shown in Fig. 4 and Fig. 5,
respectively.
The Manhattan plots in Fig. 5 indicate that it is more effective in identifying risk variants
for CD by integrating the summary statistics from auto-immune diseases, i.e. UC, PBC and T1D,
especially for combining them all. The irrelevant traits AZ, NC did not degenerate the performance
of LEP in terms of identifying risk causal variants.
The results in Fig. 4 imply that the summary statistics of PBC, T1D and UC offer different
degrees of relevant information, improving prediction accuracy (measured by AUC) from 63.39%
(±0.58%) (only CD) to 65.66% (±0.44%) (with UC), and combining them all together could improve
the prediction accuracy to 68.33% (±0.32%). These results suggested that information from diseases
of a pleiotropic relationship could indeed substantially contribute to genetic prediction accuracy.
To demonstrate the robustness of LEP on the real data, we applied LEP on the individual-level
data with each of them, their performance (63.34% (±0.53%), 63.40% (±0.54%)) was comparable
with that of working on individual-level data alone (63.39% (±0.58%)). We also applied LEP with
all the original summary statistics PBC, T1D, UC, AZ and NC, the performance slightly degraded
from 68.33% (±0.32%) to 68.05% (±0.34%) suggesting the robustness of LEP when irrelevant
summary-level datasets were included.
4 Conclusion
Restricted access to the individual-level data and the advantages of using summary-level data
motivate the recent development of many new methods for further analyzing summary-level data.
Working with the available but limited individual-level data and the abundant summary-level data
is a promising direction to make the most efficient use of existing data resources. In this study, we
propose a statistical approach, LEP, to integrating data at both the individual-level and summary-
level, and the proposed method build a bridge from the individual-level data to summary-level
data by modeling the pleiotropy. The implemented variational inference makes LEP scalable to
genome-wide data analysis. The comprehensive simulations and real data analysis demonstrate the
advantages of LEP and its wide applicabilities in practice. LEP will serve as a powerful tool for
jointly analyzing individual-level data and summary statistics.
5 Appendix
5.1 Variational Expectation-Maximization Algorithm
5.1.1 E-Step
The joint probability for the LEP model could be rewritten as , let θ = {σ2β , σ2e , pi, {αk}Kk=1} be the
collection of model parameters.
Pr(y, β˜,γ,Γ,P|X;θ)
=Pr(y|β˜,γ,X;θ)Pr(β˜;θ)Pr(γ|θ)Pr(P|Γ;θ)Pr(Γ|γ). (15)
We model the relationship between γj and Γjk as
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uk := Pr(Γjk = 1|γj = 1),
vk := Pr(Γjk = 0|γj = 0).
(16)
For the clarity of expression, we divide the joint probability into two parts, Pr(y|β˜,γ,X;θ)Pr(β˜;θ)Pr(γ|θ),
for the individual-level data and Pr(P|Γ;θ)Pr(Γ|γ) for the summary-level data. We expanded them
in the following form,
Pr(y|β˜,γ,X;θ)Pr(β˜;θ)Pr(γ|θ) = N(y|
∑
j
xj β˜jγj , σ2eI)
M∏
j=1
N(β˜j |0, σ2β)piγj (1− pi)1−γj (17)
and
Pr(P|Γ;θ)Pr(Γ|γ) =
M∏
j=1
(
K∏
k=1
(Pr(pjk|Γjk = 1)Pr(Γjk = 1|γj = 1))Γjk (Pr(pjk|Γjk = 0)Pr(Γjk = 0|γj = 1))1−Γjk
)γj
(
K∏
k=1
(Pr(pjk|Γjk = 1)Pr(Γjk = 1|γj = 0))Γjk (Pr(pjk|Γjk = 0)Pr(Γjk = 0|γj = 0))1−Γjk
)1−γj
=
M∏
j=1
(
K∏
k=1
(αkpαk−1jk uk)
Γjk(1− uk)1−Γjk
)γj ( K∏
k=1
(αkpαk−1jk (1− vk))Γjk(vk)1−Γjk
)1−γj
.
(18)
The logarithm of the marginal likelihood is
log Pr(y,P|X;θ) = log
∑
γ
∑
Γ
ˆ
β˜
Pr(y,P, β˜,γ,Γ|X,θ)dβ˜
≥
∑
γ
∑
Γ
ˆ
β˜
q(β˜,γ,Γ) log Pr(y, β˜,P,γ,Γ|X,θ)
q(β˜,γ,Γ)
dβ˜
= Eq[log Pr(y,P, β˜,γ,Γ|X;θ)− log q(β˜,γ,Γ)]
:= L(q),
(19)
where L(q) is the lower bound implied by Jensen’s inequality and the equality holds if and only
if q(β˜,γ,Γ) is the true posterior Pr(β˜,γ,Γ|y,P,X;θ). Instead of working with the marginal
likelihood, we iteratively maximizing L(q). As it is stated in the main text, we employ the following
variational distribution to make it feasible to evaluate the lower bound,
q(β˜,γ,Γ) =
M∏
j=1
qj(β˜j , γj ,Γj), (20)
where Γj = {Γj1, . . . ,ΓjK}. According to the nice property of factorized distributions in variational
inference, we can obtain the best approximation as
log qj(β˜j , γj ,Γj) = Ei6=j [log Pr(y,P, β˜,γ,Γ|X;θ)] + Const, (21)
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where the expectation is taken with respect to all of the other factors {qi(β˜i, γi,Γi)} for i 6= j.
The logarithm of the joint probability function is
log Pr(y,P, β˜,γ,Γ|X;θ) = −N2 log(2piσ
2
e)−
yTy
2σ2e
+
∑M
j=1 γj β˜jxTj y
σ2e
− 12σ2e
M∑
j=1
(
(γj β˜j)2xTj xj
)
− 12σ2e
 M∑
j=1
M∑
j′ 6=j
γj β˜jγj′ β˜j′xkxk

− M2 log(2piσ
2
β)−
1
2σ2β
M∑
j=1
β˜2j
+ log pi
∑
j
γj + log(1− pi)
∑
j
(1− γj)
+
M∑
j=1
γj
K∑
k=1
Γjk log(αkpαk−1jk uk) + (1− Γjk) log(1− uk)
+
M∑
j=1
(1− γj)
K∑
k=1
Γjk log(αkpαk−1jk (1− vk)) + (1− Γjk) log(vk).
(22)
Before proceeding, we should keep several things in our mind. First, q(β˜,γ,Γ) is the vari-
ational approximation to the posterior Pr(β˜,γ,Γ|y,X;θ). Second, we assumed q(β˜,γ,Γ) =
M∏
j=1
q(β˜j , γj ,Γj). Third, q(β˜j , γj ,Γj) = q(β˜j |γj)q(Γj |γj)q(γj).
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To take the expectation in (21), we rearrange (22) into the terms with and without index j
log Pr(y,P, β˜,γ,Γ|X;θ) = −N2 log(2piσ
2
e)−
yTy
2σ2e
+
γj β˜jxTj y
σ2e
+
∑
k 6=j γkβ˜kxTj y
σ2e
− 12σ2e
(
(γj β˜j)2xTj xj
)− 12σ2e
∑
k 6=j
(
(γkβ˜k)2xTk xk
)
− 1
σ2e
 M∑
k 6=j
γj β˜jγkβ˜kxTj xk
− 12σ2e
∑
k 6=j
∑
k′ 6=j
γkβ˜kγk′ β˜k′xTk xk′

− M2 log(2piσ
2
β)−
1
2σ2β
β˜2j −
1
2σ2β
∑
k 6=j
β˜2k
+ log pi
∑
j
γj + log(1− pi)
∑
j
(1− γj)
+
M∑
j=1
γj
K∑
k=1
Γjk log(αkpαk−1jk uk) + (1− Γjk) log(1− uk)
+
M∑
j=1
(1− γj)
K∑
k=1
Γjk log(αkpαk−1jk (1− vk)) + (1− Γjk) log(vk).
(23)
Because
Pr(Γjk|pjk, γj) = Pr(pjk|Γjk)Pr(Γjk|γj)Pr(pjk|Γjk = 1)Pr(Γjk = 1|γj) + Pr(pjk|Γjk = 0)Pr(Γjk = 0|γj) , (24)
we have
Pr(Γjk = 1|pjk, γj = 1) =
αkp
αk−1
jk uk
αkp
αk−1
jk uk + (1− uk)
=: qjk11 ,
Pr(Γjk = 0|pjk, γj = 1) = 1− uk
αkp
αk−1
jk uk + (1− uk)
=: qjk10 ,
Pr(Γjk = 1|pjk, γj = 0) =
αkp
αk−1
jk (1− vk)
αkp
αk−1
jk (1− vk) + vk
=: qjk01 ,
Pr(Γjk = 0|pjk, γj = 0) = vk
αkp
αk−1
jk (1− vk) + vk
=: qjk00 .
(25)
Now we can take expectation of log Pr(y,P, β˜,γ,Γ|X;θ) under the distribution q(β˜−j ,Γ−j., γ−j).
When γj = 1, we have
log q(β˜j |γj = 1) =
(
− 12σ2e
xTj xj −
1
2σ2β
)
β˜2j +
xTj y−
M∑
k 6=j
Ek[γkβ˜k]xTj xk
σ2e
β˜j + Const (26)
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and
q(Γjk|γj = 1) = (qjk11)Γjk(qjk10)1−Γjk . (27)
Because log q(β˜j |γj = 1) is a quadratic form, we know q(βj |γj = 1) = N(βj |µj , s2j ), where
s2j =
σ2e
xTj xj +
σ2e
σ2
β
,
µj =
xTj y−
∑
k 6=j Ek[γkβk]xTj xk
xTj xj +
σ2e
σ2
β
.
(28)
Similarly, when γj = 0, we have
log q(β˜j |γj = 0) = − 12σ2β
β˜2j + Const (29)
and
q(Γjk|γj = 0) = (qjk01)Γjk(qjk00)1−Γjk . (30)
According to Eq. (29), we know q(β˜j |γj = 0) = N(β˜j |0, σ2β). This is a very good property as it
says that the posterior distribution of β˜j will be the same as its prior if this variable is irrelevant (
γj = 0 ). Note that γj is a binary variable and then denote pij = q(γj = 1). Therefore we have
q(β˜j , γj ,Γj) =
(
pijN(µj , s2j )
K∏
k=1
q(Γjk|rj = 1)
)γj (
(1− pij)N(0, σ2β)
K∏
k=1
q(Γjk|rj = 0)
)1−γj
.
(31)
Now we evaluate the variational lower bound L(q) (19).
L(q) = Eq[log Pr(y,P, β˜,γ,Γ|X;θ)]− Eq[log q(β˜,γ,Γ)]. (32)
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The first part of Eq. (32) could be written as
Eq[log Pr(y,P, β˜,γ,Γ|X; θ)]
= −N2 log(2piσ
2
e)−
yTy
2σ2e
+
M∑
j=1
E[γj β˜j ]xTj y
σ2e
− 12σ2e
M∑
j=1
(
E[(γj β˜j)2]xTj xj
)
− 12σ2e
 M∑
j=1
M∑
j′ 6=j
E[γj β˜j ]E[γj′ β˜j′ ]xTj xj′

− M2 log(2piσ
2
β)−
1
2σ2β
M∑
j=1
E[β˜2j ]
+ log pi
∑
j
E[γj ] + log(1− pi)
∑
j
E[1− γj ]
+
M∑
j=1
pij
K∑
k=1
qk11(log(αkpαk−1jk uk)) + q
k
10 log(1− uk)
+
M∑
j=1
(1− pij)
K∑
k=1
qk01(log(αkpαk−1jk (1− vk)) + qk00 log(vk).
(33)
Because q(β˜,γ,Γ) = q(β˜|γ)q(γ)q(Γ|γ), the second term of Eq. (32) could be written as
− Eq[log q(β˜,γ,Γ)] = −Eq[log q(β˜,γ)]− Eq[log q(Γ|γ)]. (34)
The two terms of Eq. (34) could be evaluated respectively, we have
−Eq[log q(β˜,γ)] = M2 log σ
2
β +
∑
j
1
2pij(log s
2
j − log σ2β)
−
∑
j
(pij log pij + (1− pij) log(1− pij))
(35)
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and
q(Γ|γ) =
M∏
j=1
 K∏
k=1
(
αkp
αk−1
jk uk
αkp
αk−1
jk uk + (1− uk)
)Γjk (
1− uk
αkp
αk−1
jk uk + (1− uk)
)1−Γjkγj
 K∏
k=1
(
αkp
αk−1
jk (1− vk)
αkp
αk−1
jk (1− vk) + vk
)Γjk (
vk
αkp
αk−1
jk (1− vk) + vk
)1−Γjk1−γj
=
M∏
j=1
(
K∏
k=1
(qjk11)Γjk(q
jk
10)1−Γjk
)γj ( K∏
k=1
(qjk01)Γjk(q
jk
00)1−Γjk
)1−γj
,
(36)
then
−Eq[log q(Γ|γ)] = −
 M∑
j=1
pij
(
K∑
k=1
qjk11 log q
jk
11 + q
jk
10 log q
jk
10
)
+ (1− pij)
(
K∑
k=1
qjk01 log q
jk
01 + q
jk
00 log q
jk
00
) .
(37)
Now we substitute E[γj β˜j ] = pijµj , E[(γj β˜j)2] = pij(s2j + µ2j ), E[β˜2j ] = pij(s2j + µ2j ) + (1− pij)σ2β ,
E[γj ] = pij and E[1− γj ] = 1− pij .
We rearrange the lower bound
L(q) = Eq[log Pr(y,P, β˜,γ|X, θ)]− Eq[log q(β˜,γ,Γ)]
= −N2 log(2piσ
2
e)−
‖y−∑j pijµjxj‖2
2σ2e
− 12σ2e
M∑
j=1
[pij(s2j + µ2j )− (pijµj)2]xTj xj
− M2 log(2pi)−
1
2σ2β
M∑
j=1
[pij(µ2j + s2j ) + (1− pij)σ2β ]
+
∑
j
pij log(
pi
pij
) +
∑
j
(1− pij) log( 1− pi1− pij )
+
∑
j
1
2pij(log s
2
j − log σ2β)
+
M∑
j=1
pij
K∑
k=1
qjk11 log(αkp
αk−1
jk uk) + q
jk
10 log(1− uk)
+
M∑
j=1
(1− pij)
K∑
k=1
qjk01(log(αkp
αk−1
jk (1− vk)) + qjk00 log(vk)
−
 M∑
j=1
pij
(
K∑
k=1
qjk11 log q
jk
11 + q
jk
10 log q
jk
10
)
+ (1− pij)
(
K∑
k=1
qjk01 log q
jk
01 + q
jk
00 log q
jk
00
) ,
(38)
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simplifying the last three rows of Eq. (38), we could get the following equation,
M∑
j=1
pij
K∑
k=1
qjk11 log(αkp
αk−1
jk uk) + q
jk
10 log(1− uk)
+
M∑
j=1
(1− pij)
K∑
k=1
qjk01(log(αkp
αk−1
jk (1− vk)) + qjk00 log(vk)
−
 M∑
j=1
pij
(
K∑
k=1
qjk11 log q
jk
11 + q
jk
10 log q
jk
10
)
+ (1− pij)
(
K∑
k=1
qjk01 log q
jk
01 + q
jk
00 log q
jk
00
)
=
M∑
j=1
pij
K∑
k=1
log(αkpαk−1jk uk + 1− uk) +
M∑
j=1
(1− pij)
K∑
k=1
log(αkpαk−1jk (1− vk) + vk).
(39)
To get pij , we set ∂L(q)∂pij = 0, yielding
pij =
1
1 + exp(−wj) ,where wj = log
pi
1− pi +
1
2 log
s2j
σ2β
+
µ2j
2s2j
+
K∑
k=1
log
αkp
αk−1
jk uk + 1− uk
αkp
αk−1
jk (1− vk) + vk
. (40)
5.1.2 M-Step
We will update the model parameters θ = {σ2β , σ2e , pi, {αk}Kk=1} sequentially by maximizing the
lower bound L(q).
To get σ2β , we set
∂L(q)
∂σ2β
= ∂Eq[log Pr(y, β˜,γ,P|X,θ)]
∂σ2β
= 0, (41)
yielding
σ2β =
∑
j pij(µ2j + s2j )∑
j pij
. (42)
To get σ2e , we set
∂L(q)
∂σ2e
= ∂Eq[log Pr(y, β˜,γ,P|X,θ)]
∂σ2e
= −N2
1
σ2e
+ y
Ty
2σ4e
−
∑
j E[γj β˜j ]xTj y
σ4e
+ 12σ4e
M∑
j=1
(E[(γj β˜j)2]xTj xj)
+ 12σ4e
 M∑
j=1
M∑
j′ 6=j
E[γj β˜j ]E[γj′ β˜j′ ]xTj xj′
 = 0,
(43)
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yielding
σ2e =
1
N
yTy− 2∑
j
E[γj β˜j ]xTj y +
M∑
j=1
(E[(γj β˜j)2]xTj xj) +
M∑
j=1
M∑
j′ 6=j
E[γj β˜j ]E[γj′ β˜j′ ]xTj xj′

= 1
N
yTy− 2∑
j
E[γj β˜j ]xTj y +
M∑
j=1
M∑
j′=1
E[γj β˜j ]E[γj′ β˜j′ ]xTj xj′ +
M∑
j=1
(E[(γj β˜j)2]xTj xj)−
M∑
j=1
(E[γj β˜j ])2xTj xj

= 1
N
‖y−∑
j
pijµjxj‖2 +
M∑
j=1
(pij(s2j + µ2j )− (pijµj)2)xTj xj
 .
(44)
To get pi, we set ∂L(q)∂pi = 0, yielding
pi = 1
M
∑
j
pij . (45)
The parameter of the beta distribution, αk, could be obtained by maximizing L(q),
αk =
M∑
j=1
pijq
jk
11 + (1− pij)qjk01
M∑
j=1
(
pijq
jk
11 + (1− pij)qjk01
)
(− log(pjk))
. (46)
The parameters uk and vk could also be obtained by maximizing L(q), we have
uk =
∑M
j=1 pijq
jk
11∑M
j=1 pij
, (47)
vk =
∑M
j=1(1− pij)qjk00∑M
j=1(1− pij)
. (48)
5.2 ALGORITHMS
5.2.1 Basic Algorithm Steps
Now we describe an algorithm:
• Initialize {pij , µj}Mj=1, σ2β , σ2e , {αk}Kk=1, {qjk00}, {qjk11}. Let y˜ =
∑
j pijµjxj .
• E− Step: For j = 1, . . . ,M , first obtain
y˜j = y˜− pijµjxj , (49)
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and then update µj , s2j , pij and y˜ as follows
s2j =
σ2e
xTj xj + σ2e/σ2β
, (50)
µj =
xTj (y− y˜j)
xTj xj + σ2e/σ2β
, (51)
pij =
1
1 + exp(−wj) ,where wj = log
pi
1− pi +
1
2 log
s2j
σ2β
+
µ2j
2s2j
+
K∑
k=1
log
αkp
αk−1
jk uk + 1− uk
αkp
αk−1
jk (1− vk) + vk
,
(52)
y˜ = y˜j + pijµjxj . (53)
• M− Step
σ2e =
‖y− y˜‖2 + M∑
j=1
(pij(s2j + µ2j )− (pijµj)2)xTj xj
 /N,
αk =
M∑
j=1
pijq
jk
11 + (1− pij)qjk01
M∑
j=1
(
pijq
jk
11 + (1− pij)qjk01
)
(− log(pjk))
,
uk =
∑M
j=1 pijq
jk
11∑M
j=1 pij
,
vk =
∑M
j=1(1− pij)qjk00∑M
j=1(1− pij)
,
σ2β =
∑
j pij(µ2j + s2j )∑
j pij
,
pi = 1
M
∑
j
αj .
(54)
• Evaluate the lower bound L(q), check the stop criteria.
According to the definition, we could update qjk11 , q
jk
00 by
qjk11 =
αkp
αk−1
jk uk
αkp
αk−1
jk uk + (1− uk)
,
qjk00 =
vk
αkp
αk−1
jk (1− vk) + vk
.
(55)
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5.3 Condition of irrelevance between the individual-level data and summary-
level data
If the association status for the individual-level data and the k-th trait are irrelevant, the following
equation holds,
Pr(γj = 1,Γjk = 1) = Pr(γj = 1) Pr(Γjk = 1). (56)
As defined in the main text, s = Pr(γj = 1), uk = Pr(Γjk = 1|γj = 1), the left side of Eq.(56) could
be written as
Pr(γj = 1,Γjk = 1) = Pr(Γjk = 1|γj = 1)Pr(γj = 1) = uks. (57)
As
Pr(Γjk = 1) = Pr(Γjk = 1|γj = 1)Pr(γj = 1) + Pr(Γjk = 1|γj = 0)Pr(γj = 0)
= uks+ (1− vk)(1− s),
(58)
When Eq.(56) holds, we have
uks = s(uks+ (1− vk)(1− s)). (59)
We could easily get the irrelevant condition for the k-th trait with Trait T as
uk + vk = 1. (60)
5.4 MORE RESULTS IN THE SIMULATION EXPERIMENTS
In this section, we present more simulation results to the demonstrate the effectiveness of LEP. The
results contains four parts, (1) Performance of FDR control under different pleiotropy settings; (2)
Performance of FDR control with different number of summary-level datasets; (3) Performance of
risk variant identification and risk prediction under homogeneous assumption; (4) The results for
the case-control studies. As in the main text, the number of samples and the number of variants
were set to be N = 2, 000 and M = 10, 000, respectively. The heritability was pre-specified at 0.5
with the sparsity-level s = 0.05.
5.4.1 Performance of FDR control under different pleiotropy settings
In the main text, we have compared LEP with BVSR, GPA and IGESS in terms of risk variants
identification (AUC) and risk prediction under different pleiotropy settings (varying u at 0.05, 0.3,
0.7, 0.9), in this sub section, we list the results of FDR (False Discovery Rate) control. All the
datasets in this sub section are simulated under different LD setting, ρ = {0, 0.2, 0.4, 0.6, 0.8}, and
the results are based on 50 replications.
As the results shown Fig. 6, LEP could control FDR well with small or moderate LD as ρ =
{0.2, 0.4, 0.6}, we have observed slightly inflated FDR when ρ = 0.8.
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Figure 6: Performance of False Discovery Rate (FDR) Control at pre-specified level FDR= 0.1
under different pleiotropy settings and different LD. K = 1.
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5.4.2 Performance of FDR control with different number of summary-level datasets
In the main text, we have compared LEP with BVSR, GPA and IGESS in terms of variants risk
identification(AUC) and risk prediction with different number of summary-level datasets, in this
sub section, we evaluate the performance of FDR control.
According to the results in Fig. 7, LEP could also control the FDR at the pre-specified level
FDR=0.1 when ρ = {0, 0.2, 0.4, 0.6}. We have observed slightly inflated FDR when ρ = 0.8.
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Figure 7: Performance of False Discovery Rate (FDR) Control at pre-specified level FDR = 0.1
under different pleiotropy settings and different LD. Here u = 0.5
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Figure 8: Comparison of BVSR, GPA, IGESS and Lasso. Performance of risk variant identification
measured by AUC and Prediction Accuracy with a homogeneous assumption. The autoregressive
correlation ρ = 0 and the number of summary statistics data sets K = 1. All the results are
summarized based on 50 replications.
5.4.3 Results for the homogeneous assumption
We considered an extreme situation with a homogeneous assumption (the assumption of IGESS),
Γj1 = . . . = ΓjK = Γj , according to the results in Fig. 8, we could see LEP has comparable
performance with IGESS, LEP and IGESS all outperform BVSR and Lasso as they take in more
information in the analysis effectively.
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5.4.4 Case-Control Studies
In this sub section, we evaluate the performance of the case-control studies. Fig. 9 to Fig. 11
list the results of risk variants identification measured by AUC, classification accuracy, and False
Discovery Rate (FDR) respectively. We fix K = 1 and varies u at {0.05, 0.3, 0.7, 0.9} to mimic the
different pleiotropy settings. All the results are summarized based on 50 replications. They take
autoregressive correlation ρ = {0, 0.2, 0.4, 0.6, 0.8} respectively.
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Figure 9: Performance of risk variants identification measured by AUC for the case-control studies
Fig. 9 indicate that LEP and GPA have comparable performances in terms of risk variants
identification, they all outperform IGESS and BVSR.
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Figure 10: Performance of classification accuracy, which is measured by AUC evaluated on the
observed phenotype values and the predicted values, Lasso corresponds to Lasso of Gaussian type,
LassoB corresponds to Lasso of Binomial type. Lasso and LassoB have very similar performances.
Fig. 10 shows that LEP has comparable performance with BVSR where the summary-level data
is irrelevant, LEP outperforms BVSR under all other settings which shows that the information
from the summary-level data has been utilized effectively, and LEP outperforms Lasso and LassoB
with low LD (ρ = {0, 0.2, 0.4, 0.6}) and higher pleiotropy effects (u = {0.7, 0.9}.)
As the results shown Fig. 11, LEP could control FDR well with small or moderate LD as
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Figure 11: Performance of False Discovery Rate (FDR) Control at pre-specified level FDR = 0.1
for the case-control studies
ρ = {0.2, 0.4, 0.6}, we have observed slightly inflated FDR when ρ = 0.8 in the case-control studies.
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N M Souce
Alzheimer 54,162 1,136,071 Lambert et al., 2013, Nature Genetics.https://data.broadinstitute.org/alkesgroup/sumstats_formatted/
Neuroticism 170,911 1,115,394 Okbay et al., 2016a, Nature Genetics.http://ssgac.org/documents/Neuroticism_Full.txt.gz
Type 1 Diabetes 26,890 915,518 Bradfield et al., 2011, PLoS Genetics.https://www.immunobase.org/downloads/protected_data/GWAS_Data
Ulcerative Colitis 27,432 1,076,835 Jostins et al., 2012, Nature.https://data.broadinstitute.org/alkesgroup/sumstats_formatted/
Primary Biliary Cirrhosis 13,239 525,775 Cordell et al., 2015, Nature Communicationshttps://www.immunobase.org/downloads/protected_data/GWAS_Data/
Table 2: Basic information for the summary statistics for Alzheimer, Neuroticism, Type 1 diabetes,
Ulcerative Colitis, Primary Biliary Colitis
5.5 The source of the five GWAS of Summary Statistics
We list the information in Table 2 for the summary statistics in the real data analysis, the infor-
mation contains their associated sample size , their corresponding number of SNPs, their original
paper and the link for downloading the datasets.
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